Artemis:DNA-PKcs: A new drug target for cancer treatment?

Watanabe studies the molecular mechanisms of NHEJ and describes the basal state Artemis:DNA-PKcs complex for the first time.

Cells encounter DNA double-strand breaks (DSBs) every day. Because they can lead to loss of genetic information, DSBs must be repaired. Nonhomologous DNA end joining (NHEJ) is the major pathway for repairing DSBs, and the key enzymes include Artemis nuclease and DNA-dependent protein kinase catalytic subunit (DNA-PKcs). For the first time, Dr Go Watanabe and his team from the University […]

Read More… from Artemis:DNA-PKcs: A new drug target for cancer treatment?

AMP-activated kinase as a therapeutic target in prostate cancer

Prostate cancer is one of the leading causes of mortality among men worldwide.

Pharmacological treatment of prostate cancer has advanced significantly in recent years. However, while the newest therapies are initially effective in reducing tumour size, most patients eventually develop drug resistance and the recurrence of malignant spread. Professor Inés Díaz-Laviada and her team at the Alcala University in Madrid, Spain, have demonstrated that long-term treatments may induce the transformation of cancer cells […]

Read More… from AMP-activated kinase as a therapeutic target in prostate cancer